John Lohrey, MD
Hematology & Oncology · Dallas, TXNPI 1780631911
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $199 of the $319 with a category attached, or 62.4%. 10 manufacturers reported payments, led by Lilly USA, LLC at 35.1% of the total. Reporting peaked in 2019 at $137 and has fallen 87.6% since, to $17 in 2024. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 14 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$112
- Foundation Medicine, Inc.$71
- Daiichi Sankyo Inc.$27
- Sanofi$23
- Johnson & Johnson$19
- Regeneron Healthcare Solutions, Inc.$17
- plus $50 from 4 others
Across 4 payments — averaging $57,892 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$232K
What the payments were for
- Food & beverage$19962%
- Education$12038%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 2 | $112 |
| Foundation Medicine, Inc. | 3 | $71 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Sanofi | 2 | $23 |
| Johnson & Johnson | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
| AstraZeneca | 1 | $12 |
| Taiho Oncology, Inc. | 1 | $11 |
How this compares
$319 in reported general payments places this provider in the 15th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 27 | $559,440 |
| ErleadaApalutamide | 35 | $353,235 |
| XtandiEnzalutamide | 20 | $267,450 |
| Imatinib Mesylate | 11 | $59,785 |
| CreonLipase/Protease/Amylase | 39 | $40,453 |
| EliquisApixaban | 27 | $24,973 |
| Abiraterone Acetate | 23 | $11,775 |
| Fentanyl | 36 | $3,636 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 115 | $2,822 |
| Morphine Sulfate ErMorphine Sulfate | 21 | $856 |
| Prochlorperazine Maleate | 82 | $793 |
| Ondansetron Hcl | 67 | $602 |
| Gabapentin | 45 | $594 |
| Dexamethasone | 66 | $579 |
| Morphine Sulfate | 18 | $564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $19 | $353,23535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Dallas
- Edward PearsonDallas$900K
- Christopher MaiselDallas$713K
- Ashwani AgarwalDallas$275K
- Katherine WangDallas$188K
- Houston HolmesDallas$178K
- Benjamin KitchensDallas$177K
- Farrukh AwanDallas$138K
- Dai Chu LuuDallas$90K
- Luis PineiroDallas$86K
- Joan SchillerDallas$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.